Abstract:This study explores the role of Protein L‐isoaspartate (D‐aspartate) O‐methyltransferase (PCMT1) in conferring methotrexate (MTX) resistance in breast cancer cells. Through a series of experiments involving human breast cancer cell lines, the research demonstrates that PCMT1 is upregulated in MTX‐resistant cells. By employing siRNA techniques to silence the PCMT1 gene, the study observed a significant reduction in cell proliferation, migration, and invasion, alongside a decreased activation of the PI3K/Akt/STMN1 pathway, known for its role in cancer cell survival. Overall, the inhibition of PCMT1 enhanced the sensitivity of breast cancer cells to MTX, suggesting that PCMT1 might be a viable therapeutic target to overcome resistance. This study aimed to investigate whether silencing Protein L‐isoaspartate (D‐aspartate) O‐methyltransferase (PCMT1) expression can enhance the sensitivity of breast cancer cells to paclitaxel and its possible mechanism. Tumor tissues and adjacent histologically normal tissues were collected from patients with breast cancer admitted to our hospital. Human normal breast epithelial cells MCF10A, human breast cancer cells MCF‐7, and paclitaxel‐resistant breast cancer cells MCF‐7/PR were purchased. MCF‐7/PR cells were further grouped into negative control (NC) group, si‐PCMT1 group (transfected with si‐PCMT1), 740Y‐P group (treated with 740Y‐P, an activator of phosphatidylinositol 3‐kinase (PI3K)/ v‐Akt Murine Thymoma Viral Oncogene (AKT) signaling pathway), and si‐PCMT1 + 740Y‐P group (transfected with si‐PCMT1 and then treated with 740Y‐P). The expression level of PCMT1 in tissues and cells was detected by quantitative real‐time polymerase chain reaction (qRT‐PCR). Western blot analysis was used to detect the protein expression level of PCMT1 in tissues and cells as well as the protein level of p‐PI3K, PI3K, p‐Akt, Akt, and Stathmin1 (STMN1) in cells. 3‐(4,5)‐dimethylthiahiazo(‐z‐y1)‐3,5‐di‐phenytetrazoliumromide (MTT) and colony formation assays were used to determine cell viability, scratch assay was used to assess the migration ability of cells, and Transwell assay was used to assess the invasion ability of cells. The expression of PCMT1 was remarkably up‐regulated in breast cancer tissues and MCF‐7/PR cells. Silencing PCMT1 expression significantly inhibited the proliferation, migration, and invasion of MCF‐7/PR cells, and alleviated the resistance of cancer cells to paclitaxel. Additionally, silencing PCMT1 expression also inhibited the activation of PI3K/Akt/STMN1 pathway in MCF‐7/PR cells, while activating PI3K/Akt/STMN1 pathway significantly reversed the effect of silencing PCMT1 expression on MCF‐7/PR cells. PCMT1 is highly expressed in breast cancer tissues and MCF‐7/PR cells, and silencing PCMT1 expression can not only inhibit the development of breast cancer but also enhance paclitaxel sensitivity. Its mechanism of action may be achieved by inhibiting PI3K/Akt/STMN1 signaling.

Tissue Inhibitor of Metalloproteinase‐1 Protects MCF‐7 Breast Cancer Cells from Paclitaxel‐induced Apoptosis by Decreasing the Stability of Cyclin B1

Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells

High Expression of Timp-1 in Human Breast Cancer Tissues is A Predictive of Resistance to Paclitaxel-Based Chemotherapy

Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer

TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2

MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.

Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway

TIMP-1 Overexpression Does Not Affect Sensitivity to HER2-targeting Drugs in the HER2-gene-amplified SK-BR-3 Human Breast Cancer Cell Line

TIPE3 decreases breast cancer cell sensitivity to adriamycin by upregulating P-gp protein expression

SB-T-121205, a Next-Generation Taxane, Enhances Apoptosis and Inhibits Migration/invasion in MCF-7/PTX Cells

Differential Gene Expression Profiles in Paclitaxel-Induced Cell Cycle Arrest and Apoptosis in Human Breast Cancer MCF-7 Cells.

Effect of CDK7 Inhibitor THZ1 on Proliferation and Apoptosis of Breast Cancer Cells and Related Mechanism

The Role of CYP1B1 in Paclitaxel Resistance in Breast Cancer

Targeted Inhibition of Notch1 Gene Enhances the Killing Effects of Paclitaxel on Triple Negative Breast Cancer Cells.

TIMP1 Down-Regulation Enhances Gemcitabine Sensitivity and Reverses Chemoresistance in Pancreatic Cancer.

Paclitaxel Induce Apoptosis of Giant Cells Tumor of Bone Via TP53INP1 Signaling

TIPE2 Sensitizes Breast Cancer Cells to Paclitaxel by Suppressing Drug-Induced Autophagy and Cancer Stem Cell Properties.

Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells.

The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas.

Silencing MAP3K1 Expression Through RNA Interference Enhances Paclitaxel-Induced Cell Cycle Arrest in Human Breast Cancer Cells

Phenethyl isothiocyanate induced apoptosis via down regulation of Bcl-2/XIAP and triggering of the mitochondrial pathway in MCF-7 cells